Immune Checkpoint Inhibitors in Advanced NSCLC: [18F]FDG PET/CT as a Troubleshooter in Treatment Response

Cristina Ferrari 1,*, Giulia Santo 1,*, Nunzio Merenda 1, Alessia Branca 1, Paolo Mammucci 1, Pamela Pizzutilo 2, Cosmo Damiano Gadaleta 3 and Giuseppe Rubini 1

1 Nuclear Medicine Unit, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy; giuliasanto92@gmail.com (G.S.); nu.me@hotmail.it (N.M.); alessia9130@gmail.com (A.B.); paolo.mammucci@outlook.com (P.M.); giuseppe.rubini@uniba.it (G.R.)
2 Medical Thoracic Unit, IRCCS Oncologico Giovanni Paolo II, 70124 Bari, Italy; pamela.pizzutilo@gmail.com
3 Interventional and Medical Oncology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, Italy; c.gadaleta@oncologico.bari.it
* Correspondence: ferrari_cristina@inwind.it

Abstract: Introduction: The aim of this study was to investigate whether [18F]FDG PET/CT-derived semi-quantitative parameters can predict immunotherapy treatment response in non-small cell lung cancer (NSCLC) patients. Secondly, immune-related adverse events (irAEs) and lymphoid cell-rich organs activation were evaluated. Materials and Methods: Twenty-eight patients who underwent [18F]FDG PET/CT scans before and at first restaging therapy with immuno-checkpoint inhibitors (ICIs) were retrospectively analyzed. PET-based semi-quantitative parameters extracted from both scans were respectively: SUVmax and SUVpeak of the target lesion, whole-body metabolic tumor volume (MTVWB), and whole-body total lesion glycolysis (TLGWB), as well as their interval changes (∆SUVmax, ∆SUVpeak, ∆MTVWB, ∆TLGWB). These PET-derived parameters were correlated to controlled disease (CD) assessed by RECIST 1.1. IrAEs, if present, were also described and correlated with clinical benefit (CB). SUVmax of the spleen and bone marrow at restaging scans were also correlated to CB. Results: The CD was achieved in 54% of patients. Out of 28 eligible patients, 13 (46%) experienced progressive disease (PD), 7 showed SD, 7 had PR, and only in one patient CR was achieved. ∆SUVmax (p = 0.002) and ∆SUVpeak (p < 0.001) as well as ∆MTVWB (p < 0.001) and ∆TLGWB (p < 0.005) were significantly associated with PD vs. non-PD. IrAEs and lymphoid cell-rich organs activation did not correlate with CB. Conclusions: [18F]FDG PET/CT by using interval changes of PET-derived semi-quantitative parameters could represent a reliable tool in immunotherapy treatment response evaluation in NSCLC patients.

Keywords: immunotherapy; PD-1; NSCLC; [18F]FDG PET/CT; treatment response; IrAEs

1. Introduction

In the last decade, the advent of immunotherapy has paved the way for new treatment options for patients with advanced non-small cell lung cancer (NSCLC) [1]. Immuno-checkpoint inhibitors (ICIs) therapy exploits the use of antibodies that target specific molecules involved in tumor signaling, determining the suppression of cytotoxic T lymphocytes [2]. In addition, by releasing the brakes of the host-immune system, ICIs may alter the physiological homeostasis of immune response, thus leading to the development of immune-related adverse events (irAEs) [3]. To date, a standard method to evaluate the success of these innovative therapies and to identify patients who may benefit from them remains undetermined. Morphological imaging by using Response Evaluation Criteria in Solid Tumors (RECIST1.1) represents the standard modality to cytotoxic therapies response assessment [4]. To face this new clinical issue, the immune-related Response Evaluation Criteria in Solid Tumor (irRECIST) was developed [5], but their efficacy in early treatment response evaluation is still limited [6].
Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG PET/CT) represents an essential diagnostic tool in the management of NSCLC patients, from staging to treatment response evaluation. Even in the new scenario of immunotherapy, [18F]FDG PET/CT, thanks to the semi-quantitative analysis and PET-derived parameters, could represent a reliable diagnostic technique offering additional information to standard modalities [7,8]. Several studies investigated the role of PET extracting data before and/or during immunotherapy [9]. Among them, standardized uptake value (SUV), the most commonly used, was reported to be correlated to response rate. Takada et al., in 89 patients with advanced or recurrent NSCLC, showed that patients with a baseline SUVmax \(\geq 11.16\) had a significantly higher response rate compared to patients with lower SUVmax values [10]. A plethora of evidence is already available on the predictive role of volume-based PET-parameters. Some authors highlighted the predictive value of metabolic tumor volume (MTV) as well as the total lesion glycolysis (TLG) in NSCLC patients treated with ICIs [11]. Despite the increased amount of evidence, a common agreement has still not been reached.

Interestingly, [18F]FDG PET/CT could reveal irAEs before their clinical manifestation and/or laboratory test positivity. However, few literature data are still available regarding the irAEs imaging features and radiological description. Consequently, the relation between irAEs and treatment response needs further investigation [12].

This study aims to evaluate the role of [18F]FDG PET/CT-derived semi-quantitative parameters in the immunotherapy response assessment. Secondly, the detection of immune-related adverse events (irAEs) and lymphoid cell-rich organs activation were investigated in order to evaluate their possible predictive value.

2. Materials and Methods

2.1. Subject

A single-center database was retrospectively interrogated to identify patients with a history of advanced NSCLC treated with ICIs who underwent [18F]FDG PET/CT. The inclusion criteria were: (a) histologically/cytologically proven NSCLC; (b) [18F]FDG PET/CT scans before and at first restaging after the start of immunotherapy; (c) minimum follow-up of 3 months after treatment initiation; (d) radiological assessment during treatment every 8–12 weeks with CT scans, for good clinical practice; and (e) the availability of information on the best clinical response to immunotherapy.

All patients were observed for at least 6 months after the first restaging [18F]FDG PET/CT, except for those who died. Age, sex, histological subtypes, previous surgery, prior lines, and type of therapy and molecular profile (if available) were also collected.

All patients had already given their consent for the use of their data for clinical research. Our Institutional Review Board does not require the Ethical Committee’s approval for review of patients’ files.

2.2. [18F]FDG PET/CT Examination and Analysis

[18F]FDG PET/CT scans were performed with a Discovery 710 PET/CT scanner (GE, Healthcare Technologies, Milwaukee, WI, USA), and the same scanner was used for baseline and first post-treatment evaluation. All patients fasted for at least 6 h and presented a blood glucose levels less than 200 mg/dL. An intravenous injection of 3.0 MBq/kg of [18F]FDG was administered and PET/CT scanning was performed 60 min after injection. Non-contrast CT images and subsequent PET images were acquired from the skull base to the upper thigh in the supine position with the arms raised. PET image acquisition was performed for 4 min per bed in 3-dimensional acquisition mode using 7 to 10 beds. Image review and analysis were conducted on a dedicated workstations and software (AW Server 4.7; GE, Healthcare Technologies, Milwaukee, WI, USA).

All PET/CT scans were reviewed by a nuclear medicine expert who performed visual interpretation and semiquantitative analysis, documenting all pathological foci of FDG
uptake as well as the appearance of abnormal metabolism (non-physiologic) in organs possibly activated by immune-system response at first restaging PET/CT images.

Over PET parameters, the standardized uptake value (SUV) was evaluated in terms of SUV\(_{\text{max}}\) and SUV\(_{\text{peak}}\). In addition, volume-based PET parameters, MTV and TLG were obtained and used for further analysis.

PET-based semi-quantitative parameters extracted from both scans were respectively: SUV\(_{\text{max}}\) and SUV\(_{\text{peak}}\) of the target lesion (preSUV\(_{\text{maxTL}}\), postSUV\(_{\text{maxTL}}\), preSUV\(_{\text{peakTL}}\), postSUV\(_{\text{peakTL}}\)), whole-body MTV (preMTV\(_{\text{WB}}\) and postMTV\(_{\text{WB}}\)), and whole-body TLG (preTLG\(_{\text{WB}}\) and postTLG\(_{\text{WB}}\)), as well as their interval changes (ΔSUV\(_{\text{maxTL}}\), ΔSUV\(_{\text{peakTL}}\), ΔMTV\(_{\text{WB}}\) and ΔTLG\(_{\text{WB}}\)). Moreover, SUV\(_{\text{max}}\) of lymphoid cell-rich organs, spleen (pre-/post-ΔSUV\(_{\text{maxSp}}\)) and bone marrow (pre-/post-ΔSUV\(_{\text{maxBm}}\)), were collected.

### 2.3. Response Evaluation

The diagnostic assessment was performed according to Response Evaluation Criteria for Solid Tumors criteria version 1.1 (RECIST1.1), in terms of complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) at first radiological restaging. The controlled disease (CD) was defined as the achievement of CR, PR, and SD. All forementioned PET-derived parameters were correlated to treatment response.

Moreover, clinical benefit (CB) was determined considering patients’ clinical course after the last follow-up: (a) continued/stopped immunotherapy, (b) disease control/exacerbation, (c) changing to chemotherapy, or (d) death. IrAEs, if present, were also described and correlated, together with SUV\(_{\text{max}}\) of lymphoid cell-rich organs, to CB at follow up.

### 2.4. Statistical Analysis

Categorical variables were described using absolute and relative frequencies; continuous variables were described using median range. To assess the correlation between each PET/CT parameters and response groups (PD vs. no-PD), the Mann–Whitney test was used, and the results were represented graphically by box-plots. The multivariate Cox model was adopted to assess the association of PET-parameters, adjusting for gender, drugs, line of therapy, and previous lung surgery, both for CD and CB.

Finally, the association between the presence of irAEs at first restaging \([^{18}\text{F}]\text{FDG}\) PET/CT exams and CD as well as CB, was investigated using Chi-square and Fisher’s exact test. A \(p\) value less than 0.05 was considered statistically significant. All statistical analysis was performed using IBM SPSS Statistic Version 28 (IBM, Armonk, NY, USA).

### 3. Results

Between March 2016 and September 2020, a total of 47 patients with advanced NSCLC performed 103 \([^{18}\text{F}]\text{FDG}\) PET/CT exams in our Nuclear Medicine Department for ICIs treatment response evaluation. Among them, 28 patients met the inclusion criteria and were eligible for the study. Six (21%) patients were female and 22 (79%) were male. Histology revealed adenocarcinoma (79%) as the most common histotype. PD-L1 expression was available in 10/28 patients (5/10: PD-L1 expression < 50%; 5/10 PD-L1 expression > 50%).

Patients were equally treated with pembrolizumab and nivolumab (13:15). Table 1 lists of all the patients’ characteristics.

The median time between the baseline PET/CT exam and the start of immunotherapy was 38 days (range: 2–90 days), whereas the median time between PET/CT scans was 4 months (range: 2–11 months).

At baseline, PET/CT was positive in all patients, showing the presence of \([^{18}\text{F}]\text{FDG}\) uptake in lung alone (\(n = 5\)), extra-lung sites (i.e., local or distant lymph nodes, bone, adrenal glands, \(n = 3\)), and lung + extra-lung sites (\(n = 20\)).

Thirteen (46%) eligible patients, experienced progressive disease (PD) at first restaging, 7 (25%) patients showed SD, 7 (25%) had PR, and only in one patient (4%) CR was obtained. The CD was achieved in 15/28 (54%) patients (Figure 1).
Table 1. Patients’ characteristics.

| Variable                        | Number   |
|---------------------------------|----------|
| Total Number of Patients        | 28       |
| Median age at diagnosis (years) | 65 (range 48–87) |
| Sex                             |          |
| Male                            | 22 (79%) |
| Female                          | 6 (21%)  |
| Histological variant            |          |
| Adenocarcinoma                  | 22 (79%) |
| Squamous Cell Carcinoma         | 4 (14%)  |
| Others                          | 2 (7%)   |
| Previous lung surgery           |          |
| No                              | 21 (75%) |
| Yes                             | 7 (25%)  |
| Immunotherapy                   |          |
| First line                      | 8 (29%)  |
| ≥ Second line                   | 20 (71%) |
| Drugs                           |          |
| Nivolumab                       | 15 (54%) |
| Pembrolizumab                   | 13 (46%) |

Figure 1. A 60-year old man affected by non-small cell lung cancer underwent [18F]FDG PET/CT before and after immunotherapy. PET/CT showed high [18F]FDG uptake into primary lesion in the left lung (red arrows) and in the liver (yellow arrows), as secondary disease localizations. After four pembrolizumab cycles, patient underwent morphological and functional revaluation. [18F]FDG PET/CT showed no more uptake in primary tumor and a reduction of metabolic activity in liver lesions. CeCT evaluation confirmed partial response (PR) to immunotherapy. CeCT: contrast enhanced computed tomography; [18F]FDG PET: Fluorine-18 fluorodeoxyglucose positron emission tomography.

None of parameters extracted from the PET/CT before starting immunotherapy (preSUV\textsubscript{maxTL}, preSUV\textsubscript{peakTL}, preMTV\textsubscript{WB}, preTLG\textsubscript{WB}) showed a significant correlation with radiological response. Conversely, ΔSUV\textsubscript{maxTL} (p = 0.002) and ΔSUV\textsubscript{peakTL} (p < 0.001) as well as ΔMTV\textsubscript{WB} (p < 0.001) and ΔTLG\textsubscript{WB} (p < 0.005) were significantly associated with PD vs. non-PD. No difference was showed between the pembrolizumab and nivolumab treated-groups. In the subgroup with available PD-L1 status, the ligand expression was shown to be statistically correlated with baseline SUV\textsubscript{max} (p = 0.017) and baseline SUV\textsubscript{peak} (p = 0.03). The relation between CD and ΔSUV\textsubscript{maxTL}, ΔSUV\textsubscript{peakTL}, ΔMTV\textsubscript{WB}, ΔTLG\textsubscript{WB} is reported in the box plots in Figure 2.
liver lesions. CeCT evaluation confirmed partial response (PR) to immunotherapy. CeCT: contrast enhanced computed tomography; \([18F]\)FDG PET: Fluorine-18 fluorodeoxyglucose positron emission tomography.

None of parameters extracted from the PET/CT before starting immunotherapy (pre-SUV\textsubscript{max}TL, preSUV\textsubscript{peak}TL, preMTV\textsubscript{WB}, preTLG\textsubscript{WB}) showed a significant correlation with radiological response. Conversely, \(\Delta\)SUV\textsubscript{max}TL \((p = 0.002)\) and \(\Delta\)SUV\textsubscript{peak}TL \((p < 0.001)\) as well as \(\Delta\)MTV\textsubscript{WB} \((p < 0.001)\) and \(\Delta\)TLG\textsubscript{WB} \((p < 0.005)\) were significantly associated with PD vs. non-PD. No difference was showed between the pembrolizumab and nivolumab treated-groups. In the subgroup with available PD-L1 status, the ligand expression was shown to be statistically correlated with baseline SUV\textsubscript{max} \((p = 0.017)\) and baseline SUV\textsubscript{peak} \((p = 0.03)\).

The relation between CD and \(\Delta\)SUV\textsubscript{max}TL, \(\Delta\)SUV\textsubscript{peak}TL, \(\Delta\)MTV\textsubscript{WB}, \(\Delta\)TLG\textsubscript{WB} is reported in the box plots in Figure 2.

---

Figure 2. Box plots of PET-derived parameters which significantly correlated with progressive (PD) vs. non-progressive (no-PD) disease. CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; SUV: standardized uptake value; TLG: total lesion glycolysis; MTV: metabolic tumor volume. The midline, box edges and outers bars indicate the median, first and third quartiles, and the upper and lower whiskers, respectively. Dots (◦) and asterisks (*) represent outliers.

The median follow-up was 11 months (range: 4–48). Among all patients, 18 (64%) experienced CB: all of them continued immunotherapy and were alive at last follow-up. Conversely, 10 patients (36%) showed no-CB. Among them, 8 (80%) had disease exacerbation and stopped immunotherapy, while 2 (20%) died soon after the first restaging.

Five patients showed immuno-related findings on PET/CT. Notably, in two out of the five patients, diffuse thyroid \([18F]\)FDG uptake, as for thyroiditis, was detected. PET/CT finding of colitis was observed in one patient only, who reported persistent diarrhea during pembrolizumab treatment. A pattern of immunotherapy-related arthritis and pneumonitis associated with sarcoid reaction was shown on PET/CT scans of the last two patients, respectively. Table 2 shows the demographics of patients who developed irAEs and the most representative cases are depicted in Figure 3.

---

**Table 2. Patients’ irAEs.**

| Patients (n = 5) | Age, Sex | Disease   | Therapy   | irAEs                    | Final Outcome |
|-----------------|----------|-----------|-----------|--------------------------|---------------|
| 1               | 58, F    | NSCLC     | Nivolumab | Thyroiditis              | PD            |
| 2               | 61, F    | NSCLC     | Nivolumab | Thyroiditis              | SD            |
| 3               | 64, M    | NSCLC     | Pembrolizum | Colitis                | PR            |
| 4               | 64, M    | NSCLC     | Nivolumab | Arthritis                | PD            |
| 5               | 60, M    | NSCLC     | Nivolumab | Pneumonitis and sarcoid reaction | PR            |

F: female; M: male; NSCLC: non-small cell lung cancer; irAEs: immune-related adverse events; PR: partial response; PD: progressive disease; SD: stable disease.
Table 2. Patients' irAEs.

| Patients (n = 5) Age, Sex Disease Therapy | irAEs | Final Outcome |
|-----------------------------------------|-------|---------------|
| 1 58, F NSCLC Nivolumab                 | Thyroiditis | PD            |
| 2 61, F NSCLC Nivolumab                | Thyroiditis | SD            |
| 3 64, M NSCLC Pembrolizumab            | Colitis    | PR            |
| 4 64, M NSCLC Nivolumab                | Arthritis  | PD            |
| 5 60, M NSCLC Nivolumab                | Pneumonitis and sarcoid reaction | PR |

F: female; M: male; NSCLC: non-small cell lung cancer; irAEs: immune-related adverse events; PR: partial response; PD: progressive disease; SD: stable disease.

Figure 3. Most representative cases of irAEs detected on [18F]FDG PET/CT in our sample. (a) Immunotherapy-related thyroiditis: 58yo female with advanced lung adenocarcinoma under nivolumab immunotherapy. After 8 cycles of therapy, asymptomatic thyroiditis was incidentally found on restaging PET/CT (red circle). The same scan showed progressive metabolic disease (PMD), confirmed by follow-up. (b) Immune-related colitis: 64yo man affected by stage IV NSCLC, with pleural involvement and lymph nodes metastasis detected on basal PET/CT. During pembrolizumab treatment, the patient reported persistent diarrhea. Restaging PET/CT scan showed partial metabolic response (PMR) and increased [18F]FDG uptake in the colon region consistent with immune-mediated colitis (green dotted square). (c) Immune-related pneumonitis and sarcoid-like reaction: 56yo man with stage IIIA NSCLC who received nivolumab monotherapy as first line treatment. Basal PET/CT showed [18F]FDG uptake both in the left pulmonary lesion and hilar bilateral lymphadenopathies. First restaging [18F]FDG PET/CT showed increase in bilateral mediastinal and hilar lymphadenopathy involvement and diffuse lung parenchymal uptake, suggesting a sarcoid-like reaction together with a pneumonitis (yellow dotted square), the latter supported by the presence of dyspnea and dry cough. Nivolumab was continued and subsequent PET/CT scan showed a partial metabolic response (PMR).

Three out of the five patients with irAEs PET/CT findings reached CD (1 SD; 2 PR), while the other two showed PD on morphological imaging. No statistically significant correlation was reached between irAEs and CD ($p = 0.429$). Similarly, three out of five patients showed CB at follow-up but no significant correlation was found ($p = 0.229$).
None of lymphoid cell-rich organs metabolic PET-parameters was significantly correlated to CB. All statistical results are detailed in Tables 3 and 4.

Table 3. PET-derived parameters and interval change.

| Overall (n = 28) | PET Parameters | Median ± SD | p     |
|-----------------|----------------|-------------|-------|
| CD              | preSUV<sub>maxTL</sub> | 13.0 ± 5.4  | 0.751 |
|                 | preSUV<sub>peakTL</sub> | 10.0 ± 4.2  | 0.525 |
|                 | preTLG<sub>WB</sub> | 425,737 ± 586.6 | 0.130 |
|                 | preMTV<sub>WB</sub> | 203.0 ± 302.9 | 0.387 |
|                 | ∆SUV<sub>max TL</sub> | −0.5 ± 6.7  | 0.003 |
|                 | ∆SUV<sub>peak TL</sub> | −0.04 ± 7.2  | <0.001 |
|                 | ∆TLG<sub>WB</sub> | 242.8 ± 1375.6 | <0.001 |
|                 | ∆MTV<sub>WB</sub> | 34.8 ± 443.9 | 0.022 |

| CB              | postSUV<sub>maxSp</sub> | 2.3 ± 0.6  | 0.586 |
|                 | postSUV<sub>maxBM</sub> | 2.0 ± 0.4  | 0.464 |

CD: disease control; CB: clinical benefit; SUV: standardized uptake value; TLG: total lesion glycolysis; MTV: metabolic tumor volume; TL: target lesion; WB: whole-body; Sp: spleen; BM: bone marrow.

Table 4. Predictive role of patients' clinical pathological features and PET-derived parameters in multivariate analysis.

| Patients (n = 28) | Controlled Disease | Clinical Benefit | Variables                     | HR (95% CI) | p Value | HR (95% CI) | p Value |
|------------------|--------------------|------------------|--------------------------------|-------------|---------|-------------|---------|
|                  |                    |                  | Sex (male, female)             | 0.113       | 0.487   | 0.289       | 0.079   |
|                  |                    |                  | Histological variant           | 0.246       | 0.287   | 0.022       | 0.927   |
|                  |                    |                  | Previous lung surgery          | 0.036       | 0.835   | −0.233      | 0.185   |
|                  |                    |                  | Line immunotherapy             | −0.390      | 0.022   | 0.289       | 0.113   |
|                  |                    |                  | Drugs                          | 0.292       | 0.131   | −0.100      | 0.627   |
|                  |                    |                  | SUV<sub>maxTL</sub> (<11.4 vs. >11.4) | 0.072      | 0.717   | −           | −       |
|                  |                    |                  | TLG<sub>WB</sub> (<194.1 vs. >194.1) | 0.215      | 0.272   | −           | −       |
|                  |                    |                  | MTV<sub>WB</sub> (<54 vs. >54)  | 0.215       | 0.272   | −           | −       |
|                  |                    |                  | SUV<sub>peakTL</sub> (<9 vs. >9) | 0.005       | 0.979   | 0.056       | 0.787   |
|                  |                    |                  | ∆SUV<sub>maxTL</sub> (<0.3 vs. >0.3) | −0.359  | 0.061   | −           | −       |
|                  |                    |                  | ∆TLG<sub>WB</sub> (<4.35 vs. >4.35) | −0.790     | <0.001  | 0.622       | <0.001  |
|                  |                    |                  | ∆MTV<sub>WB</sub> (<−2.55 vs. >−2.55) | −0.426     | 0.024   | 0.678       | <0.001  |
|                  |                    |                  | ∆SUV<sub>peakTL</sub> (<−0.21 vs. >−0.21) | −0.503     | 0.007   | 0.156       | 0.449   |

SUV: standardized uptake value; TLG: total lesion glycolysis; MTV: metabolic tumor volume; TL: target lesion; WB: whole-body.
4. Discussion

The advent of immunotherapy in clinical practice and the approval of several drugs for advanced solid tumors led to the development of new challenges for imaging. In this scenario, $^{18}$F-FDG PET/CT, a consolidate tool in the evaluation of lung cancer, was proposed as a promising marker for immunotherapy treatment response evaluation, providing useful and unique information [13].

In the last few years, there has been a growing interest in the evaluation of PET-derived parameters as predictors of response [14]. This study pointed out that metabolic changes during immunotherapy statistically correlate with treatment response as well as with CB. Notably, the interval changes of all PET-derived parameters showed a significant decrease in responders, potentially representing a marker of long-term clinical response. Similar results were reached by Nobashi et al., in their study on 40 patients affected by different cancer types, where they found a significant correlation between PET parameters’ variation and best overall response at one year [15].

Other authors assessed the predictive role of $^{18}$F-FDG PET/CT by semiquantitative analysis. In 2019, Evangelista et al. retrospectively studied 32 patients with metastatic lung cancer under nivolumab treatment. SUV$_{max}$WB was significantly higher in patients with PD compared with those with SD and PR, whereas a similar trend was shown for TLG$_{WB}$ and MTV$_{WB}$, both higher in non-responders than responders, even without a statistical significance [16]. Conversely, in other studies, SUV$_{max}$ was unable to predict response. However, volume-based PET parameters were extracted. In this context, a bicentric Italian study performed an analysis in a bigger cohort of 92 patients, demonstrating that those with PD had higher MTV median values compared to those with controlled disease [17]. Similarly, Polverani and colleagues observed a significant association of MTV and TLG of the primary lesions with PD, since lower MTV and TLG values were associated with non-PD status [18]. In our study, we emphasized the variation of PET-derived parameters during immunotherapy in NSCLC patients as a potential biomarker of treatment response.

Even if PD-L1 status was not available for all patients included in our sample, the analysis revealed its significant correlation with baseline SUVs: increased values of SUVs were detected in patients with PD-L1 expression higher than 50%. Albeit with a limited number of cases, this finding, supported by the literature data, suggests a potential role of $^{18}$F-FDG PET/CT in predicting PD-L1 status [19,20].

Interestingly, in the multivariate analysis, it was shown that immunotherapy employed as a second or more line of therapy was significantly correlated to a better response rate. We can speculate that this finding could be associated with the growing evidence that cytotoxic chemotherapy and radiotherapy could impact tumor ligand expression, determining changes in cell PD-L1 expression as well as in the tumor microenvironment [21,22].

There is still a lack of data on the role of irAEs in predicting the response to ICIs. A first 2017 retrospective trial reported data from 134 NSCLC patients treated with nivolumab. A total of 51% of patients had irAEs with a statistically significant longer progression free survival (PFS) and OS [23]. In another prospective trial, 30% of irAEs were found in a total of 38 patients who showed a better objective overall response (ORR) [24]. Though promising, the data are conflicting. The most reported frequent irAEs were endocrinopathy (hypothyroidism 4–8%, hyperthyroidism 0–5%), skin rashes (5–11%), and hepatitis (2–11%). The most severe ones were pneumonitis (3–5%), colitis (1–2%), hypophysitis (2%), and adrenal failure (0–1%), estimated to occur in 69% of patients [25].

Even if the occurrence of irAEs seems to be associated with better response and prolonged overall survival (OS) [26], few data are available in the literature about the prognostic role of irAEs detected on PET and response. In a study conducted by Sachpekidis et al. in a cohort of metastatic melanoma patients, irAEs on PET/CT correlated with response to immunotherapy—patients who developed at least one irAE had a significantly longer PFS than those without irAEs [27,28].

In our sample, any statistically significant correlation was reached, probably due to the few immune-related events frequency registered. However, three out of five patients who
showed irAE on PET/CT experimented CD or CB. Moreover, as PET/CT could monitor the metabolic changes in peripheral lymphoid organs and related ones [29], we conducted a semi-quantitative evaluation on lymphoid cell-rich organs, such as the spleen and bone marrow but none of PET-derived parameters were shown to be statistically significant. Conversely, Nobashy et al. conducted a similar analysis reporting a significant increase of SUV\textsubscript{max} of the spleen in those patients who did not show any clinical benefit after the start of immunotherapy [15].

Despite the retrospective nature of the present study and the small population size that could impact the results, our study aimed to help highlight the emerging and promising role of PET imaging in predicting response in the field of immunotherapy.

5. Conclusions

\[^{[18]}\text{F}\]FDG PET/CT could represent a reliable and efficacious diagnostic tool in immunotherapy treatment response evaluation in advanced NSCLC patients. The decrease of all tumor parameters at first restaging PET/CT results in a predictive role for immunotherapy response and could represent a useful biomarker to estimate treatment response evaluation. Further research is needed to confirm these preliminary data and to explore the interesting field of irAEs findings on PET/CT and their correlation with response.

Author Contributions: Conceptualization, C.F.; methodology, G.S.; formal analysis, N.M.; data curation, A.B. and P.P.; writing—original draft preparation, G.S. and A.B.; writing—review and editing, C.F. and P.M.; supervision, C.D.G.; project administration, G.R. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Given the retrospective nature of the study, our Institutional Review Board does not require the Ethical Committee’s approval for the review of the patients’ files.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Lim, J.U.; Yoon, H.K. Potential Predictive Value of Change in Inflammatory Cytokines Levels Subsequent to Initiation of Immune Checkpoint Inhibitor in Patients with Advanced Non-Small Cell Lung Cancer. Cytokine 2021, 138, 155363. [CrossRef]
2. Sardaro, A.; Ferrari, C.; Carbonara, R.; Altini, C.; Lavelli, V.; Rubini, G. Synergism between Immunotherapy and Radiotherapy in Esophageal Cancer: An Overview of Current Knowledge and Future Perspectives. Cancer Biother. Radiopharm. 2021, 36, 123–132. [CrossRef]
3. Weinmann, S.C.; Pisetsky, D.S. Mechanisms of Immune-Related Adverse Events during the Treatment of Cancer with Immune Checkpoint Inhibitors. Rheumatology 2019, 58, vii59–vi67. [CrossRef]
4. Schwartz, L.H.; Litière, S.; de Vries, E.; Ford, R.; Gwyther, S.; Mandrekar, S.; Shankar, L.; Bogaerts, J.; Chen, A.; Dancey, J.; et al. RECIST 1.1—Update and Clarification: From the RECIST Committee. Eur. J. Cancer 2016, 62, 132. [CrossRef]
5. Subbiah, V.; Chuang, H.H.; Gambhire, D.; Kairemo, K. Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives. Diagnostics 2017, 7, 10. [CrossRef]
6. Evangelista, L.; Sepulcri, M.; Pasello, G. PET/CT and the Response to Immunotherapy in Lung Cancer. Curr. Radiopharm. 2020, 13, 177. [CrossRef]
7. Frega, S.; Maso, A.D.; Pasello, G.; Cuppari, L.; Bonanno, L.; Conte, P.; Evangelista, L. Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. Cancers 2020, 12, 1303. [CrossRef]
8. Grizzi, F.; Castello, A.; Lopci, E. Is It Time to Change Our Vision of Tumor Metabolism Prior to Immunotherapy? Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 1072–1079. [CrossRef]
9. Aide, N.; de Pontdeville, M.; Lopci, E. Evaluating Response to Immunotherapy with \(^{18}\text{F}\)-FDG PET/CT: Where Do We Stand? Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 1019–1021. [CrossRef]
10. Takada, K.; Toyokawa, G.; Yoneshima, Y.; Tanaka, K.; Okamoto, I.; Shimokawa, M.; Wakisaka, S.; Haro, A.; Oseegawa, A.; Tagawa, T.; et al. \(^{18}\text{F}\)-FDG Uptake in PET/CT Is a Potential Predictive Biomarker of Response to Anti-PD-1 Antibody Therapy in Non-Small Cell Lung Cancer. Sci. Rep. 2019, 9, 13362. [CrossRef]
11. Chardin, D.; Paquet, M.; Schiappa, R.; Darcourt, J.; Bailleux, C.; Poudex, M.; Sciizza, A.; Ilie, M.; Benzaquen, J.; Martin, N.; et al. Original Research: Baseline Metabolic Tumor Volume as a Strong Predictive and Prognostic Biomarker in Patients with Non-Small Cell Lung Cancer Treated with PD1 Inhibitors: A Prospective Study. *J. Immunother. Cancer* 2020, 8, 643. [CrossRef]

12. Costa, L.B.; Queiroz, M.A.; Barbosa, F.G.; Nunes, R.F.; Zaniboni, E.C.; Ruiz, M.M.; Jardim, D.; Marin, J.F.G.; Cerri, G.G.; Buchpiguel, C.A. Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism. *Radiographics* 2020, 41, 120–143. [CrossRef]

13. Liberini, V.; Laudicella, R.; Capozza, M.; Huellner, M.W.; Burger, I.A.; Baldari, S.; Terreno, E.; Deandreis, D. The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers. *Molecules* 2021, 26, 2201. [CrossRef]

14. Ranieri, G.; Marech, I.; Asabella, A.N.; di Palo, A.; Porcelli, M.; Lavelli, V.; Rubini, G.; Ferrari, C.; Gadaleta, C.D. Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation. *Int. J. Mol. Sci.* 2017, 18, 1937. [CrossRef]

15. Nobashi, T.; Baratto, L.; Reddy, S.A.; Srinivas, S.; Toriihara, A.; Hatami, N.; Yohannan, T.K.; Mittra, E. Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT. *Clin. Nucl. Med.* 2019, 44, e272–e279. [CrossRef]

16. Evangelista, L.; Cuppari, L.; Menis, J.; Bonanno, L.; Frega, S.; Pasello, G. 18F-FDG PET/CT in Non-Small-Cell Lung Cancer: A Real World Experience. *Cancers* 2021, 13, 1634. [CrossRef] [PubMed]

17. Monaco, L.; Gemelli, M.; Gotuzzo, I.; Bauckneht, M.; Crivellaro, C.; Genova, C.; Cortinovis, D.; Zullo, L.; Ammoni, L.C.; Bernasconi, D.P.; et al. Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience. *Cancers* 2021, 13, 2654. [CrossRef] [PubMed]

18. Polverari, G.; Ceci, F.; Bertaglia, V.; Reale, M.L.; Rampado, O.; Gallio, E.; Passera, R.; Liberini, V.; Scapoli, P.; Arena, V.; et al. 18F-FDG PET Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival. *Cancers* 2020, 12, 1163. [CrossRef]

19. Takada, K.; Toyokawa, G.; Okamoto, T.; Baba, S.; Kozuma, Y.; Matsubara, T.; Haratake, N.; Akamine, T.; Takamori, S.; Katsura, M.; et al. Metabolic Characteristics of Programmed Cell Death-Ligand 1-Expressing Lung Cancer on 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. *Cancer Med.* 2017, 6, 2552–2561. [CrossRef] [PubMed]

20. Evangelista, L. The Prediction of Response to Immunotherapy in Non-Small Cell Lung Cancer Patients by 18F-FDG PET/CT. *J. Thorac. Dis.* 2019, 11, E221–E223. [CrossRef] [PubMed]

21. Omori, S.; Kenmotsu, H.; Abe, M.; Watanabe, R.; Sugino, T.; Kobayashi, H.; Nakashima, K.; Wakuda, K.; Ono, A.; Taira, T.; et al. Changes in Programmed Death Ligand 1 Expression in Non-Small Cell Lung Cancer Patients Who Received Anticancer Treatments. *Int. J. Clin. Oncol.* 2018, 23, 1052–1059. [CrossRef]

22. Kang, J.; Zhang, C.; Zhong, W.-Z. Neoadjuvant Immunotherapy for Non–Small Cell Lung Cancer: State of the Art. *Cancer Commun.* 2021, 41, 287–302. [CrossRef]

23. Haratani, K.; Hayashi, H.; Chiba, Y.; Kudo, K.; Yonesaka, K.; Kato, R.; Kaneda, H.; Hasegawa, Y.; Tanaka, K.; Takeda, M.; et al. Association of Immune-Related Adverse Events with Nivolumab Efficacy in Non–Small-Cell Lung Cancer. *JAMA Oncol.* 2018, 4, 374–378. [CrossRef] [PubMed]

24. Sato, K.; Akamatsu, H.; Murakami, E.; Sasaki, S.; Kanai, K.; Hayata, A.; Tokudome, N.; Akamatsu, K.; Koh, Y.; Ueda, H.; et al. Correlation between Immune-Related Adverse Events and Efficacy in Non-Small Cell Lung Cancer Treated with Nivolumab. *Lung Cancer* 2018, 115, 71–74. [CrossRef] [PubMed]

25. Villadolid, J.; Amin, A. Immune Checkpoint Inhibitors in Clinical Practice: Update on Management of Immune-Related Toxicities. *Transl. Lung Cancer Res.* 2015, 4, 560. [PubMed]

26. Grangeon, M.; Tomasini, P.; Chaleat, S.; Jeanon, A.; Souquet-Bressand, M.; Khobra, N.; Bermudez, J.; Trigui, Y.; Greillier, L.; Blanchon, M.; et al. Association Between Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–Small-Cell Lung Cancer. *Clin. Lung Cancer* 2019, 20, 201–207. [CrossRef] [PubMed]

27. Sachpekidis, C.; Kopp-Schneider, A.; Hakim-Meibodi, L.; Dimitrakopoulou-Stauros, A.; Hassel, J.C. 18 F-FDG PET/CT Longitudinal Studies in Patients with Advanced Metastatic Melanoma for Response Evaluation of Combination Treatment with Vemurafenib and Ipilimumab. *Melanoma Res.* 2019, 29, 178–186. [CrossRef]

28. Ferrari, C.; Maggialetti, N.; Masi, T.; Nappi, A.G.; Santo, G.; Asabella, A.N.; Rubini, G. Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview. *J. Pers. Med.* 2021, 11, 217. [CrossRef]

29. Jin, P.; Li, J.; Meng, Y.; Wu, L.; Bai, M.; Yu, J. PET/CT Metabolic Patterns in Systemic Immune Activation: A New Perspective on the Assessment of Immunotherapy Response and Efficacy. *Cancer Lett.* 2021, 520, 91–99. [CrossRef] [PubMed]